艾隆科技(688329.SH):控股子公司擬購買資產
格隆匯6月6日丨艾隆科技(688329.SH)公佈,公司控股子公司艾隆專項基於業務發展需要,擬與滁州築醫台簽署《築醫台(滁州)美好醫院集成創新基地廠房銷售合同》(暫定名),合同約定艾隆專項向滁州築醫台購買其開發建設的位於安徽省滁州市泉州路300號的創新基地標準化廠房19號,為艾隆專項以及公司其他子公司艾隆科技(滁州)有限公司(簡稱“滁州艾隆”)、醫谷(滁州)航空醫療研究院有限公司(簡稱“醫谷研究院”)等用於開展運營。創新基地是集學術交流、研發場景展示、裝配生產於一體,覆蓋醫院從建築設計到正式運營全流程的“前店後場產業模式協同創新平台”,本次交易有助於推動公司實現戰略目標。本次交易對價合計人民幣16,133,987元(含增值税),資金來源為艾隆專項自有或自籌資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.